The FDA has approved Astepro (azelastine nasal spray, from Meda), a reformulation of Astelin, for the treatment of seasonal allergic rhinitis. In clinical trials of 1400 patients, Astepro users reported improved symptom relief and tolerance with fewer reports of bitter taste and nasal discomfort as compared to Astelin.

Astepro is expected to be launched before the next allergic rhinitis season.

For more information call (732) 564-2200 or visit